Members of our management team are attending the 2025 International HypoPARAthyroidism Conference, hosted by the HypoPARAthyroidism Association, this October 3-5.     Andreas G. Moraitis, MD, our Sr. Vice President of Clinical Development, will present the recently announced 12-week and 6-month topline results from the Phase 2 clinical trial evaluating our potential once-weekly parathyroid hormone (PTH) replacement therapy.     We look forward to engaging with members of the HP community in person in Grapevine, TX, and invite those who cannot physically attend to register virtually: https://lnkd.in/exPSnS6E